These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8885123)

  • 41. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bupropion sustained release: side effect profile.
    Settle EC
    J Clin Psychiatry; 1998; 59 Suppl 4():32-6. PubMed ID: 9554319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
    Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Managing rapid metabolizers of antidepressants.
    Kraus RP; Diaz P; McEachran A
    Depress Anxiety; 1996-1997; 4(6):320-7. PubMed ID: 9166660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
    Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
    Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.
    Kirchheiner J; Brøsen K; Dahl ML; Gram LF; Kasper S; Roots I; Sjöqvist F; Spina E; Brockmöller J
    Acta Psychiatr Scand; 2001 Sep; 104(3):173-92. PubMed ID: 11531654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
    Shulman RW; Ozdemir V
    Can J Psychiatry; 1997 Jun; 42 Suppl 1():4S-9S. PubMed ID: 9220124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study.
    Worrall SP; Almond MK; Dhillon S
    Nephron Clin Pract; 2004; 97(3):c83-9. PubMed ID: 15292684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults.
    Kharasch ED; Neiner A; Kraus K; Blood J; Stevens A; Miller JP; Lenze EJ
    Clin Pharmacol Ther; 2020 Nov; 108(5):1036-1048. PubMed ID: 32386065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
    Owen JR; Nemeroff CB
    Depress Anxiety; 1998; 7 Suppl 1():24-32. PubMed ID: 9597349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
    Mihara K; Otani K; Suzuki A; Yasui N; Nakano H; Meng X; Ohkubo T; Nagasaki T; Kaneko S; Tsuchida S; Sugawara K; Gonzalez FJ
    Psychopharmacology (Berl); 1997 Sep; 133(1):95-8. PubMed ID: 9335086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
    Vandel P
    World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
    Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
    Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
    Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
    Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.